Skip to main content

August 2022, Vol 12, No 8

Targeting HER2 with the antibody–drug conjugate fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) provided clinically meaningful benefits for patients with HER2-low metastatic breast cancer, according to findings presented at the 2022 American Society of Clinical Oncology Annual Meeting. Read More ›

We now know what will follow the Oncology Care Model (OCM). On June 27, 2022, the Centers for Medicare & Medicaid Services’ (CMS) Innovation Center announced the voluntary Enhancing Oncology Model (EOM). Read More ›

There are several methods that can be used to gain a better perspective when determining the success of an oncology practice and its operations. Financial evaluation, access to care, quality metrics, and employee engagement are just a few of the operational elements that are important to consider, especially as they relate to the overall patient experience. Read More ›

More than 50% of adults with refractory or relapsed large B-cell lymphoma (LBCL) who were not deemed candidates for high-dose chemotherapy and hematopoietic stem-cell transplantation (HSCT) had complete responses (CRs) following treatment with lisocabtagene maraleucel (Breyanzi). Read More ›

In the United States, black or African-American patients with cancer and COVID-19 were more likely than non-Hispanic white patients to have delays or disruptions in cancer treatment during the pandemic, according to results of the American Society of Clinical Oncology (ASCO) Survey on COVID-19 in Oncology Registry that were presented during the 2022 ASCO meeting. Read More ›

The new proposed Centers for Medicare & Medicaid Services (CMS) Enhancing Oncology Model sets forth the expectation that medical practices will actively engage with patients as they go about their daily lives between office visits, tracking symptoms, and monitoring adverse events that can lead to costly medical interventions. Read More ›

The following clinical trials represent a selection of key studies currently recruiting patients with head and neck cancer for inclusion in investigations of new therapies and new regimens of existing treatments for the disease. Each clinical trial description includes the NLM Identifier to be used as a reference with This information can help oncology practice managers and providers direct eligible patients to one of these clinical trials. Read More ›